Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Glenmark Pharmaceuticals Ltd

GLENMARK:NSI

Glenmark Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,694.85
  • Today's Change32.75 / 1.97%
  • Shares traded29.94k
  • 1 Year change+125.86%
  • Beta1.1384
Data delayed at least 15 minutes, as of Nov 01 2024 13:13 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Glenmark Pharmaceuticals Limited is an India-based research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over the counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company’s offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. The Company is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.

  • Revenue in INR (TTM)120.21bn
  • Net income in INR-15.73bn
  • Incorporated1977
  • Employees14.99k
  • Location
    Glenmark Pharmaceuticals LtdB D S MargChakala, Off Western Express HighwayAndheri (E),MUMBAI 400099IndiaIND
  • Phone+91 2 240189999
  • Fax+91 2 240189986
  • Websitehttps://glenmarkpharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Natco Pharma Ltd.42.21bn16.37bn251.28bn4.02k15.35--13.785.9591.3791.37235.68--------10,510,210.00--12.33--14.2583.4073.0538.7725.16--91.13--18.9647.7213.8194.0916.59-4.7114.87
Laurus Labs Ltd50.53bn1.31bn264.86bn6.01k201.926.4048.585.242.432.4393.7076.700.6021.183.068,412,186.001.5510.132.5216.4753.4447.632.5812.830.58181.810.402313.00-16.5517.07-79.6811.3621.6821.67
Gland Pharma Ltd58.58bn7.22bn272.02bn4.22k37.67--24.884.6443.8343.83355.57--------13,890,770.00--13.23--14.5661.0055.5812.3322.92--34.66--7.2656.2922.61-1.1011.3224.02--
Emcure Pharmaceuticals Ltd-100.00bn-100.00bn272.13bn11.15k--------------------------7.14--13.93--59.29--7.81------0.0011.237.14-6.3621.35-5.93--
J B Chemicals and Pharmaceuticals Ltd35.92bn5.87bn304.58bn5.31k53.02--41.458.4836.9936.99226.16--------6,764,044.00--15.77--18.8966.2761.1816.3416.06--21.04--33.0810.6316.2234.8423.3640.1537.42
Suven Pharmaceuticals Ltd9.34bn2.40bn334.35bn1.05k138.89--112.9935.789.469.4636.75--------8,883,019.00--23.17--26.2056.5958.8525.7333.21--33.74--18.63-21.5622.71-26.9922.41-1.83--
Piramal Pharma Ltd87.04bn453.30m354.33bn6.72k787.954.4844.044.070.34070.340766.3659.910.57991.404.8812,954,040.000.302--0.428--63.69--0.5208--0.56037.490.3771--15.39--109.56------
Ajanta Pharma Ltd44.91bn8.75bn382.82bn7.84k44.0610.4137.838.5269.5569.55356.94294.360.97381.334.165,725,128.0018.9716.6123.2920.4775.7773.2219.4819.312.1349.880.008831.2012.4515.4138.8116.10-14.9710.76
IPCA Laboratories Ltd82.12bn5.77bn403.09bn17.34k69.88--42.484.9122.7422.74323.71--------4,737,502.00--10.33--13.5267.0859.166.8412.25--15.41--12.8623.3915.3516.134.2417.9021.67
GlaxoSmithKline Pharmaceuticals Limited35.60bn6.75bn459.47bn3.21k68.4927.4761.8012.9039.6039.60209.3198.741.012.5914.8511,088,370.0019.2411.0136.0917.8861.7055.7718.9612.251.38554.800.0088192.076.212.00-2.915.78-36.029.86
Glenmark Pharmaceuticals Ltd120.21bn-15.73bn478.18bn14.99k------3.98-55.78-46.50425.96--------8,020,026.00--1.02--1.4363.9359.47-12.711.43--1.78--56.981.983.67-1,018.93---5.894.56
Abbott India Ltd59.28bn12.39bn615.78bn3.81k49.70--46.9610.39583.08583.082,789.54--------15,541,480.00--20.92--28.5945.2844.2020.9017.26--119.46--77.069.359.7226.5221.6831.0852.32
Alkem Laboratories Ltd127.32bn20.54bn691.00bn17.28k33.64--29.025.43171.81171.811,064.87--------7,369,150.00--11.88--17.5062.2159.2616.2913.94--9.12--29.829.2111.4882.4718.75-13.3020.11
Data as of Nov 01 2024. Currency figures normalised to Glenmark Pharmaceuticals Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

22.05%Per cent of shares held by top holders
HolderShares% Held
HSBC Global Asset Management (Hong Kong) Ltd.as of 31 Dec 20239.95m3.53%
Norges Bank Investment Managementas of 30 Jun 20249.18m3.25%
Capital Research & Management Co. (World Investors)as of 30 Sep 20248.76m3.10%
HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 30 Sep 20248.71m3.09%
Mirae Asset Investment Managers (India) Pvt Ltd.as of 30 Sep 20247.90m2.80%
The Vanguard Group, Inc.as of 02 Oct 20245.49m1.95%
Dimensional Fund Advisors LPas of 03 Oct 20243.74m1.33%
Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 30 Sep 20243.31m1.17%
Invesco Asset Management (India) Pvt Ltd.as of 30 Sep 20243.05m1.08%
BlackRock Fund Advisorsas of 03 Oct 20242.12m0.75%
More ▼
Data from 30 Jun 2024 - 15 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.